Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies
- PMID: 3683485
- DOI: 10.1056/NEJM198712103172402
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies
Abstract
Since chemotherapy for metastatic breast cancer is not curative, consideration of the quality of life is important in selecting a treatment regimen. We conducted a randomized trial comparing continuous chemotherapy, administered until disease progression was evident, with intermittent therapy, whereby treatment was stopped after three cycles and then repeated for three more cycles only when there was evidence of disease progression. Each approach was tested with doxorubicin combined with cyclophosphamide or with cyclophosphamide combined with methotrexate, fluorouracil, and prednisone. Intermittent therapy resulted in a significantly worse response (P = 0.02 by Mann-Whitney test), a significantly shorter time to disease progression (relative risk based on proportional-hazards model, 1.8; 95 percent confidence interval, 1.4 to 2.4), and a trend toward shorter survival (relative risk, 1.3; confidence interval, 0.99 to 1.6). The quality of life was expressed as linear-analogue self-assessment scores for physical well-being, mood, pain, and appetite and as a quality-of-life index. It improved significantly during the first three cycles, when all patients received treatment. Thereafter, intermittent therapy was associated with worse scores for physical well-being (by 23 percent of scale; 95 percent confidence interval, 11 to 35 percent), mood (25 percent; 13 to 37 percent), and appetite (12 percent; 0 to 24 percent) and for the quality-of-life index as indicated by the patient (14 percent; 5 to 23 percent) and the physician (16 percent; 7 to 26 percent). Changes in the quality of life were independent prognostic factors in proportional-hazards models of subsequent survival. We conclude that, as tested, continuous chemotherapy is better than intermittent chemotherapy for advanced breast cancer.
Similar articles
-
Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association.N Engl J Med. 1991 Nov 7;325(19):1342-8. doi: 10.1056/NEJM199111073251904. N Engl J Med. 1991. PMID: 1922236 Clinical Trial.
-
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-5-S17-9. Semin Oncol. 1997. PMID: 9374084 Clinical Trial.
-
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83. doi: 10.1093/jnci/djh188. J Natl Cancer Inst. 2004. PMID: 15265969 Clinical Trial.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
Hormono-chemotherapy in the treatment of advanced breast cancer.J Steroid Biochem. 1985 Dec;23(6B):1129-34. doi: 10.1016/0022-4731(85)90031-7. J Steroid Biochem. 1985. PMID: 3912617 Review.
Cited by
-
Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.Br J Cancer. 1990 Jan;61(1):133-6. doi: 10.1038/bjc.1990.27. Br J Cancer. 1990. PMID: 2297484 Free PMC article.
-
Current applications of health-related quality-of-life assessment in oncology.Support Care Cancer. 1997 Mar;5(2):100-4. doi: 10.1007/BF01262565. Support Care Cancer. 1997. PMID: 9069608
-
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.Springerplus. 2013 Aug 21;2:391. doi: 10.1186/2193-1801-2-391. eCollection 2013. Springerplus. 2013. PMID: 24024086 Free PMC article.
-
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.Br J Cancer. 1991 May;63(5):794-8. doi: 10.1038/bjc.1991.176. Br J Cancer. 1991. PMID: 2039705 Free PMC article. Clinical Trial.
-
Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study.Cancer Res Treat. 2022 Oct;54(4):1038-1052. doi: 10.4143/crt.2021.698. Epub 2022 Feb 4. Cancer Res Treat. 2022. PMID: 35130417 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical